Cis(Z)‐clopenthixol and haloperidol in chronic schizophrenic patients ‐ a double‐blind clinical multicentre investigation

Publisher Website
Google Scholar
Abstract
Sixty‐three chronic schizophrenic in‐patients were included in the double‐blind, double‐dummy clinical trial comparing antipsychotic activity and side effects of cis(Z)‐clopenthixol and haloperidol. Test treatment was administered at least 8 and in most cases 12 weeks with clinical evaluations including BPRS, NOSIE‐30, CGI and single side effects done at weeks 0, 2, 4, 8, and 12. The average end‐of‐trial doses were 40 mg cis(Z)‐clopenthixol and 10 mg haloperidol. Statistically significant improvements of total BPRS‐score and Thinking disturbance were registered with both drugs from week 2 onwards. At week 12 when 36 patients were receiving test treatment total BPRS‐score was reduced by 31% in the cis(Z)‐clopenthixol group and by 17% in the haloperidol group. At week 4 Thinking disturbance was reduced by 32% in the cis(Z)‐clopenthixol group and by 16% in the haloperidol group ‐ these findings constituted the only significant difference between test drugs. Compared to the BPRS‐results less improvements and no differences between test drugs were registered with NOSIE‐30 and CGI. Any trends towards different frequency and severity of side effects were in the favour of cis(Z)‐clopenthixol.